JP2020504110A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020504110A5 JP2020504110A5 JP2019533396A JP2019533396A JP2020504110A5 JP 2020504110 A5 JP2020504110 A5 JP 2020504110A5 JP 2019533396 A JP2019533396 A JP 2019533396A JP 2019533396 A JP2019533396 A JP 2019533396A JP 2020504110 A5 JP2020504110 A5 JP 2020504110A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- pharmaceutical composition
- subject
- seq
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022115212A JP7500662B2 (ja) | 2016-12-23 | 2022-07-20 | 抗第ＸＩ／ＸＩａ因子抗体による処置法 |
| JP2024091065A JP2024116221A (ja) | 2016-12-23 | 2024-06-05 | 抗第ＸＩ／ＸＩａ因子抗体による処置法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662438654P | 2016-12-23 | 2016-12-23 | |
| US62/438,654 | 2016-12-23 | ||
| US201762589851P | 2017-11-22 | 2017-11-22 | |
| US62/589,851 | 2017-11-22 | ||
| PCT/IB2017/058345 WO2018116267A2 (en) | 2016-12-23 | 2017-12-22 | Methods of treatment with anti-factor xi/xia antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022115212A Division JP7500662B2 (ja) | 2016-12-23 | 2022-07-20 | 抗第ＸＩ／ＸＩａ因子抗体による処置法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020504110A JP2020504110A (ja) | 2020-02-06 |
| JP2020504110A5 true JP2020504110A5 (OSRAM) | 2021-04-30 |
| JP7110199B2 JP7110199B2 (ja) | 2022-08-01 |
Family
ID=61022382
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019533396A Active JP7110199B2 (ja) | 2016-12-23 | 2017-12-22 | 抗第ＸＩ／ＸＩａ因子抗体による処置法 |
| JP2022115212A Active JP7500662B2 (ja) | 2016-12-23 | 2022-07-20 | 抗第ＸＩ／ＸＩａ因子抗体による処置法 |
| JP2024091065A Pending JP2024116221A (ja) | 2016-12-23 | 2024-06-05 | 抗第ＸＩ／ＸＩａ因子抗体による処置法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022115212A Active JP7500662B2 (ja) | 2016-12-23 | 2022-07-20 | 抗第ＸＩ／ＸＩａ因子抗体による処置法 |
| JP2024091065A Pending JP2024116221A (ja) | 2016-12-23 | 2024-06-05 | 抗第ＸＩ／ＸＩａ因子抗体による処置法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20200231701A1 (OSRAM) |
| EP (1) | EP3558370A2 (OSRAM) |
| JP (3) | JP7110199B2 (OSRAM) |
| KR (2) | KR102702288B1 (OSRAM) |
| CN (2) | CN118320078A (OSRAM) |
| AU (2) | AU2017383537B2 (OSRAM) |
| CA (1) | CA3048157A1 (OSRAM) |
| IL (2) | IL316673A (OSRAM) |
| WO (1) | WO2018116267A2 (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6799530B2 (ja) | 2014-10-01 | 2020-12-16 | メディミューン リミテッド | チカグレロルに対する抗体および使用方法 |
| JOP20200312A1 (ar) | 2015-06-26 | 2017-06-16 | Novartis Ag | الأجسام المضادة للعامل xi وطرق الاستخدام |
| TW201802121A (zh) | 2016-05-25 | 2018-01-16 | 諾華公司 | 抗因子XI/XIa抗體之逆轉結合劑及其用途 |
| IL316673A (en) * | 2016-12-23 | 2024-12-01 | Novartis Ag | Factor XI/XIA FOR USE IN PREVENTING, TREATING, MANAGING OR REDUCING THE RISK OF STROKE OR THROMBOEMBOLISM IN A SUBJECT AFFLICTED WITH END STAGE RENAL DISEASE |
| JP7139332B2 (ja) | 2016-12-23 | 2022-09-20 | ノバルティス アーゲー | 第ｘｉ因子抗体および使用方法 |
| US20210347915A1 (en) * | 2018-09-20 | 2021-11-11 | Phasebio Pharmaceuticals, Inc. | Methods of reversing ticagrelor activity |
| CN117186232B (zh) * | 2019-04-16 | 2024-07-30 | 四川科伦博泰生物医药股份有限公司 | 抗FXI/FXIa抗体及其用途 |
| CN110423278B (zh) * | 2019-08-08 | 2020-07-17 | 上海博槿生物科技有限公司 | 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用 |
| JP2023507795A (ja) * | 2019-12-20 | 2023-02-27 | アントス セラピューティクス， インコーポレイテッド | 第ＸＩ／ＸＩａ因子抗体の医薬製剤および投薬レジメン |
| TW202405022A (zh) * | 2022-06-24 | 2024-02-01 | 美商安瑟斯治療公司 | 與抗因子ｘｉ／因子ｘｉａ抗體之組合療法 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
| KR900005995A (ko) | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | 변형 인터류킨-2 및 그의 제조방법 |
| JP2989002B2 (ja) | 1988-12-22 | 1999-12-13 | キリン―アムジエン・インコーポレーテツド | 化学修飾顆粒球コロニー刺激因子 |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| WO1991006570A1 (en) | 1989-10-25 | 1991-05-16 | The University Of Melbourne | HYBRID Fc RECEPTOR MOLECULES |
| US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
| DE69123241T2 (de) | 1990-12-14 | 1997-04-17 | Cell Genesys Inc | Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen |
| ATE249840T1 (de) | 1991-12-13 | 2003-10-15 | Xoma Corp | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| FR2686901A1 (fr) | 1992-01-31 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant. |
| US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
| US5834252A (en) | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| MX9700764A (es) | 1994-07-29 | 1997-05-31 | Smithkline Beecham Plc | Compuestos novedosos. |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US20070190059A1 (en) * | 1996-01-17 | 2007-08-16 | Smithkline Beecham Corporation | Antithrombotic agents |
| MA24512A1 (fr) * | 1996-01-17 | 1998-12-31 | Univ Vermont And State Agrienl | Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose |
| US20030235587A1 (en) * | 1998-08-07 | 2003-12-25 | Feuerstein Giora Z. | Anticoagulant agents useful in treatment of thrombosis |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| EP0985039B1 (en) | 1997-06-12 | 2008-02-20 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| WO2000007626A1 (en) * | 1998-08-07 | 2000-02-17 | Smithkline Beecham Corporation | Use of anti-coagulation factor antibodies as long-lasting protective agents |
| ATE217889T1 (de) * | 1998-08-28 | 2002-06-15 | Genentech Inc | Humane antikörper gegen faktor ix/ixa |
| EP2275557A1 (en) | 2000-04-12 | 2011-01-19 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| PL360060A1 (en) * | 2000-05-15 | 2004-09-06 | Smithkline Beecham Corporation | Antithrombotic agents |
| EP3002298B1 (en) * | 2007-11-21 | 2019-08-28 | Oregon Health & Science University | Anti-factor xi monoclonal antibodies and methods of use thereof |
| DK2297207T3 (en) * | 2008-06-19 | 2018-12-03 | Prothix Bv | USING ANTI-FACTOR XI ANTIBODIES FOR PREVENTION OR TREATMENT OF THROME CREATION |
| ES2720594T3 (es) * | 2008-12-18 | 2019-07-23 | Univ Oregon Health & Science | Anticuerpos anti-fXI y métodos de uso |
| IL212911A0 (en) * | 2011-05-16 | 2011-07-31 | Omrix Biopharmaceuticals Ltd | Immunoglobulin reduced in thrombogenic contaminants and preparation thereof |
| SG10201609322QA (en) * | 2012-05-10 | 2017-01-27 | Bayer Pharma AG | Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof |
| JOP20200312A1 (ar) * | 2015-06-26 | 2017-06-16 | Novartis Ag | الأجسام المضادة للعامل xi وطرق الاستخدام |
| IL316673A (en) * | 2016-12-23 | 2024-12-01 | Novartis Ag | Factor XI/XIA FOR USE IN PREVENTING, TREATING, MANAGING OR REDUCING THE RISK OF STROKE OR THROMBOEMBOLISM IN A SUBJECT AFFLICTED WITH END STAGE RENAL DISEASE |
-
2017
- 2017-12-22 IL IL316673A patent/IL316673A/en unknown
- 2017-12-22 EP EP17832998.3A patent/EP3558370A2/en active Pending
- 2017-12-22 KR KR1020197021024A patent/KR102702288B1/ko active Active
- 2017-12-22 US US16/472,641 patent/US20200231701A1/en not_active Abandoned
- 2017-12-22 KR KR1020247029148A patent/KR20240134248A/ko active Pending
- 2017-12-22 AU AU2017383537A patent/AU2017383537B2/en active Active
- 2017-12-22 IL IL267519A patent/IL267519B2/en unknown
- 2017-12-22 CN CN202410462229.0A patent/CN118320078A/zh active Pending
- 2017-12-22 CN CN201780087088.7A patent/CN110325211A/zh active Pending
- 2017-12-22 JP JP2019533396A patent/JP7110199B2/ja active Active
- 2017-12-22 CA CA3048157A patent/CA3048157A1/en active Pending
- 2017-12-22 WO PCT/IB2017/058345 patent/WO2018116267A2/en not_active Ceased
-
2022
- 2022-02-11 US US17/670,270 patent/US20230002507A1/en not_active Abandoned
- 2022-07-20 JP JP2022115212A patent/JP7500662B2/ja active Active
-
2024
- 2024-06-05 JP JP2024091065A patent/JP2024116221A/ja active Pending
- 2024-07-23 US US18/781,421 patent/US20250197522A1/en active Pending
- 2024-12-23 AU AU2024287181A patent/AU2024287181A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020504110A5 (OSRAM) | ||
| JP2017506626A5 (OSRAM) | ||
| RU2013149792A (ru) | Способы лечения состояний, связанных с masp-2 зависимой активацией комплемента | |
| JP2019513726A5 (OSRAM) | ||
| JP2017537105A5 (OSRAM) | ||
| WO2017064615A1 (en) | Use of c5 inhibitors in transplant associated microangiopathy | |
| JP2018523684A5 (OSRAM) | ||
| JP2020513757A5 (OSRAM) | ||
| JP2016537380A5 (OSRAM) | ||
| JP2023002547A (ja) | 慢性腎疾患の治療のためのデュラグルチド | |
| Ikegami et al. | Feasible usage of ABO incompatible grafts in living donor liver transplantation | |
| FI3852617T3 (fi) | Vasta-ainefragmenttien käyttö tikagrelorin aktiivisuuden kääntämiseen | |
| US20020094332A1 (en) | Method of prophylaxis against large myocardial infractions | |
| EP3345924A1 (en) | Use of cd47 antibodies | |
| WO2021213523A1 (zh) | 抗pd-1抗体和抗ctla-4抗体的组合在预防或治疗癌症中的用途 | |
| CN113924099A (zh) | 针对免疫球蛋白轻链的单克隆抗体与抗体产生细胞和其他免疫细胞上的cd38细胞膜分子的组合治疗al淀粉样变性 | |
| Biswas et al. | A retrospective study on patients of Guillain-Barre syndrome treated with therapeutic plasma exchange at a tertiary care hospital in Western Maharashtra | |
| CA2473786A1 (en) | Method of prophylaxis against large myocardial infarctions | |
| Bujnowska et al. | Outcomes of prolonged treatment with intravenous immunoglobulin infusions for acute antibody-mediated rejection in kidney transplant recipients | |
| Kavanagh et al. | POS-035 a phase 3 study to support iptacopan registration in atypical hemolytic uremic syndrome (aHUS): overview of APPELHUS study design considerations | |
| Kykalos et al. | Successful Simultaneous Pancreas-Kidney Re-transplantation in a Highly Human Leukocyte Antigen–Sensitized Patient | |
| WO2025130748A1 (zh) | 一种抗凝血因子XI/XIa抗体制剂 | |
| JP7756452B2 (ja) | 肺、腎臓、または肝臓の線維症疾患の処置に使用するためのｐｓｍｐアンタゴニスト | |
| JP2020143156A (ja) | 心血管リスクを低減させる方法 | |
| JPWO2020061465A5 (OSRAM) |